N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=33 Impact of Oral Antibiotic Treatment on C. Difficile
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
N/A N=780 Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Clostridium Difficile
Primary: C. Difficile Acquisition Rates — 13.2; 10.4 C. diff acquisition per patient days — p=0.611
N/A N=403 Antimicrobial Stewardship Program for Clostridium Difficile Infection.
Clostridium Difficile · Enterocolitis, Pseudomembranous
Primary: Number of Participants With Clostridium Difficile Infection Recurrence. — 34; 21 Participants — p=0.56
Phase 4 N=674 Screening to Prophylax Against Clostridium Difficile Infection -
Clostridium Difficile Infection
Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…
Phase 2 N=13 Early FMT for C.Difficile
Clostridium Difficile
Primary: Clinical Remission Rates — 3; 2 Participants
Phase 2 N=413 A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Clostridium Difficile · Clostridium Infections
Primary: Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up. — 2; 7 Participants — p=0.045
Phase 2 N=200 Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
Clostridium Infections
Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants
Phase 2 N=133 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Enterocolitis Clostridium Difficile Recurrent
Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 4 N=51 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
Clostridium Difficile Infection · Prophylaxis · Vancomycin
Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Phase 4 N=34 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
Clostridium Difficile Infection
Primary: C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool — 11; 6 Participants
Phase 3 N=17,535 Clostridium Difficile Vaccine Efficacy Trial
Clostridium Difficile Infection
Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes
N/A N=600 Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries
Clostridium Difficile Infection
Primary: Patient Demographics — 54; 46; 63; 29 participants
N/A N=189 Molecular Epidemiology of Clostridium Difficile Infections in Children
Clostridium Difficile Infections
Primary: Clostridium Difficile Infections Strain Type Based on Restriction Endonuclease Analysis — 3 cases of BI/NAP1/027
Phase 2 N=206 Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Clostridium Difficile Infection Recurrence
Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 76; 59 Participants — p=0.0488
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
N/A N=418 Targeted Infection Control in Long-term Care
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Phase 3 N=92 Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
Recurrent Clostridium Difficile Infection · Primary Clostridium Difficile Infection
Primary: Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the Treatment — 4; 9 Participants — p=0.228
Phase 2 N=68 Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route
C. Difficile
Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958
Phase 4 N=144 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Phase 2 N=50 The ICON Study: Outcomes After FMT for Patients With IBD and CDI
Inflammatory Bowel Diseases · Clostridium Difficile Infection
Primary: Number of Participants With FMT Failure — 4 Participants
Phase 1 N=140 Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
Clostridium Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, After Each Vaccine Dose — 0; 0; 0; 8 Participants
Phase 4 N=8 Effects of Intravenous (IV) Omadacycline on Gut Microbiome
Microbial Colonization
Primary: Phylum Level Mean Proportional Relative Abundance — 0.167; 0.0271; 0.686; 0.0391 % gram positive (+) for phylum
Phase 3 N=267 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
Clostridium Difficile Infection (CDI)
Primary: Efficacy of RBX2660 Compared to Placebo Through 8 Weeks — 57.5; 70.6 Model-estimated percent of participants
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate